Category

NASDAQ

Digital Health Acquisition Corp. Announces Filing of a Preliminary Extension Proxy Statement for a Stockholder Meeting on October 20, 2022 NASDAQ

Digital Health Acquisition Corp. Announces Filing of a Preliminary Extension Proxy Statement for a Stockholder Meeting on October 20, 2022

BOCO RATON, FL / ACCESSWIRE / October 10, 2022 / Digital Health Acquisition Corp. (the "Company" or "Digital Health") (NASDAQ:DHAC), today announces the filing of a definitive proxy statement to hold a special meeting of its stockholders on October 20, 2022 at 9:30 am Eastern Time to extend the date…
bubmag
October 10, 2022
Dow drops over 600 points, Nasdaq nearly 4% lower as job gains remain steady, complicating Fed effort to lower prices NASDAQ

Dow drops over 600 points, Nasdaq nearly 4% lower as job gains remain steady, complicating Fed effort to lower prices

Stocks fell on Friday as traders evaluated September’s jobs report, which showed the unemployment rate continuing to decline and sparked an increase in interest rates. The Dow Jones Industrial Average fell 682 points, or 2.3%, to 29,264.39. The S&P 500 lost 3% to 3,642.68. The Nasdaq Composite slid 3.9% to…
bubmag
October 7, 2022
Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K NASDAQ

Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K

FORT COLLINS, CO / ACCESSWIRE / October 6, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audit of the Company's financial statements for fiscal 2021 is complete and that…
bubmag
October 7, 2022
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing NASDAQ

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

ZÜRICH, SWITZERLAND / ACCESSWIRE / October 5, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that on September 29, 2022, it received a…
bubmag
October 5, 2022